1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
Binding of [3H] monohydroxytamoxifen in ovarian carcinoma
Article first published online: 23 AUG 2005
DOI: 10.1111/j.1471-0528.1983.tb09306.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 90, Issue 8, pages 751–758, August 1983
Additional Information
How to Cite
HOLT, J. A., JORDAN, V. C., TATE, A. C. and LORINCZ, M. A. (1983), Binding of [3H] monohydroxytamoxifen in ovarian carcinoma. BJOG: An International Journal of Obstetrics & Gynaecology, 90: 751–758. doi: 10.1111/j.1471-0528.1983.tb09306.x
Publication History
- Issue published online: 23 AUG 2005
- Article first published online: 23 AUG 2005
- Received 25 November 1982 Accepted 12 March 1983
- Abstract
- Article
- References
- Cited By
Summary. A monoclonal antibody (D-547) against human breast cancer oestrogen receptor was used to demonstrate that the oestrogen receptor in ovarian epithelial carcinomata binds [3H]monohydroxytamoxifen. This binding was observed in sedimentation velocity analyses of both cytosol and nuclear compartments. Binding of [3H]monohydroxytamoxifen to the antibody-recognized moiety could be inhibited by diethylstilboestrol or oestradiol, but not by androgen, progestin or corticoid, indicating oestrogen specificity for the binding site. The sedimentation coefficient of the antibody-recognized [3H]monohydroxytamoxifen binding moiety was similar to that when 16α-[125I]iodo-oestradiol was used as the ligand.